coronavirus Archives - Drugs in Context

The treatment of mild upper respiratory tract infections – a position paper with recommendations for best practice

Andrew Smith, Peter Kardos, Oliver Pfaar, Winfried Randerath, Guillermo Estrada Riolobos, Fulvio Braido, Laura Sadofsky

Article Type

Review

Published

25 Jul 2023

This position paper addresses the treatment of mild upper respiratory tract infections (MURTIs) and provides recommendations for best practice.

Addressing COVID-19 vaccine hesitancy

George Kassianos, Joan Puig-Barberà, Hannah Dinse, Martin Teufel, Özlem Türeci, Shanti Pather

Article Type

Review

Published

20 Jun 2022

This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.

Vitamins, supplements and COVID-19: a review of currently available evidence

Lauren Speakman, Sarah Michienzi, Melissa Badowski

Article Type

Review

Published

06 Oct 2021

The purpose of this review was to analyse clinical trials regarding vitamins and supplements for the treatment of COVID-19 infections.

Presentation and pathophysiology of neuro-COVID

Josef Finsterer, Fulvio Alexandre Scorza, Carla Alexandra Scorza

Article Type

Letter-to-the-Editor

Published

12 Aug 2021

Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.

The race to a COVID-19 vaccine: opportunities and challenges in development and distribution

Rodrigo M Burgos, Melissa E Badowski, Emily Drwiega, Samaneh Ghassemi, Nikki Griffith, Fischer Herald, Mikayla Johnson, Renata O Smith, Sarah M Michienzi

Article Type

Commentary

Published

16 Feb 2021

This article discusses the unprecedented toll of COVID-19 and how it jumpstarted the race towards potential COVID-19 vaccinations, which have been developed in less than a year. It discusses how this feat was accomplished, and how clinical development, manufacturing scale-up and distribution are occurring in parallel for the four COVID-19 vaccine front-runners. It also discusses the many challenges that still lie ahead.